NASDAQ:MREO

Mereo BioPharma Group Q2 2025 Earnings Results & Report

Mereo BioPharma Group logo
$0.26 -0.02 (-5.45%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$0.26 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mereo BioPharma Group missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.02 versus the -$0.01 consensus estimate, while revenue of $500 thousand fell short of the $7.80 million estimate by $7.30 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Mereo BioPharma Group EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 8 quarters

Mereo BioPharma Group Revenue Results

Actual Revenue
$500 thousand
Expected Revenue
$7.80 million
Beat/Miss
Missed by -$7.30 million
YoY Revenue Growth
N/A

Mereo BioPharma Group Q2 2025 Earnings FAQ

Mereo BioPharma Group (NASDAQ:MREO) reported earnings of -$0.02 per share for Q2 2025, missing the consensus estimate of -$0.01. The report was announced on Tuesday, August 12, 2025.

Mereo BioPharma Group reported revenue of $500 thousand for Q2 2025, against a consensus estimate of $7.80 million.

Mereo BioPharma Group Earnings Headlines

Mereo BioPharma Reports Third Quarter 2026 Financial Results
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Mereo BioPharma Group PLC ADR
See More Mereo BioPharma Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mereo BioPharma Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your email.

About Mereo BioPharma Group

Mereo BioPharma Group (NASDAQ:MREO) plc is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer. Established in 2015 and based in the United Kingdom, the company advances drug candidates that it has acquired or licensed from other pharmaceutical developers.

Its rare-disease programs include setrusumab, an investigational antibody being developed for osteogenesis imperfecta, and alvelestat, an investigational oral drug being studied for lung disease associated with alpha-1 antitrypsin deficiency. Mereo has also developed oncology candidates, including navicixizumab, an investigational antibody designed to target pathways involved in tumor growth.

Mereo’s programs are intended for patients in international markets, with development conducted through clinical studies and collaborations. The company is led by Chief Executive Officer Denise Scots-Knight. Its candidates remain investigational and are subject to clinical and regulatory review.

View Mereo BioPharma Group Profile